Phaseline

Companies › Translational Sciences

Translational Sciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TS23
Monoclonal antibody to α2-antiplasmin
SERPINF2Phase 2Pulmonary Embolism; Ischemic StrokeNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05408546TS23Phase 2Pulmonary EmbolismCardiovascularNov 2026
NCT05948566TS23Phase 2Ischemic StrokeNeurologyJul 2028

Targets

SERPINF2 (1)

Companies with the same targets

–

Companies built like this

Ever Neuro Pharma AMO Pharma Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Edgewise Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.